Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin)
To find out the frequency of Extensively Drug Resistant (XDR) and pre-XDR tuberculosis in clinical isolates of Multi-Drug Resistant (MDR) Tuberculosis (TB) by determining the susceptibilities against Levofloxacin and Amikacin (classical second line antituberculosis drugs). Adescriptive cross-section...
Gespeichert in:
| Veröffentlicht in: | Journal of the College of Physicians and Surgeons--Pakistan 2015-05, Vol.25 (5), p.337-341 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 341 |
|---|---|
| container_issue | 5 |
| container_start_page | 337 |
| container_title | Journal of the College of Physicians and Surgeons--Pakistan |
| container_volume | 25 |
| creator | Mirza, Irfan Ali Khan, Farooq Ahmad Khan, Khursheed Ali Satti, Luqman Ghafoor, Tahir Fayyaz, Muhammad |
| description | To find out the frequency of Extensively Drug Resistant (XDR) and pre-XDR tuberculosis in clinical isolates of Multi-Drug Resistant (MDR) Tuberculosis (TB) by determining the susceptibilities against Levofloxacin and Amikacin (classical second line antituberculosis drugs).
Adescriptive cross-sectional study.
Microbiology Department, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from September 2011 to August 2013.
Amikacin (AK) and Levofloxacin (LEVO) were obtained in chemically pure form from Sigma (Taufkirchen, Germany). The breakpoint concentration used for AK was 1.0 µg/ml and for LEVO 2.0 µg/ml. Mycobacterial Growth Indicator Tube (MGIT) 960 system was used to carry out drug susceptibility testing as per recommended protocol.
A total of 3 MDR-TB isolates (3%) turned out to be XDR-TB based upon simultaneous resistance to injectable second line antituberculosis drug AK and one of the fluoro-quinolones (LEVO). A total of 24 MDR-TB isolates (24%) were found to be pre-XDR based upon resistance to LEVO alone. Treatment status record of patients with XDR and pre-XDRTB isolates revealed that majority of patients had received fluoroquinolones (FQs) during the course of treatment.
XDR-TB has started to emerge in MDR-TB isolates in our set up. The worrying sign is the high frequency of pre-XDR tuberculosis. Urgent steps need to be taken to stem the tide of pre-XDR-TB in our population. It is thus recommended to develop facilities to carry out drug susceptibility testing to monitor the status of pre-XDR and XDR-TB in our population. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1683573279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A414824627</galeid><sourcerecordid>A414824627</sourcerecordid><originalsourceid>FETCH-LOGICAL-g278t-f6382dca7ec51d8843244d833c1260ca9c70db65a039f181d2d29833abc929ff3</originalsourceid><addsrcrecordid>eNp9UdtKxDAQLaK46-ovSMCX9aHSJr2kj8uyXmDBFwXfSppMSjRt1iSV3e_yB81eBAWRwCQ5OWfOzOQoGqcFTeMyxONwTjCOCS1eRtGZc69JQvKU0tNohIskoUVOx9HnYu2hd-oD9AaxXqCVhRh-YMIOLbLglPOs98gPDVg-aBMApHrEteoVZxopZzTz4JCRqBu0V_F_ysGpvg1i5txO7YCbYB6Swc7RoamGDyO1WTMebLaVsU69bS_X59GJZNrBxWGfRM-3i6f5fbx8vHuYz5Zxi0vqY1kQigVnJfA8FZRmBGeZoITwNPTPWcXLRDRFzhJSyZSmAgtchWfW8ApXUpJJNN3nXVnzPoDzdaccB61ZD2ZwdRgyyUuCyypQr_bUlmmoVS-Nt4xv6fUsSzOKswKXgXXzByssAZ0KAwCpAv5LcHmoYGg6EPXKqo7ZTf39f-QL7Mmb6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683573279</pqid></control><display><type>article</type><title>Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mirza, Irfan Ali ; Khan, Farooq Ahmad ; Khan, Khursheed Ali ; Satti, Luqman ; Ghafoor, Tahir ; Fayyaz, Muhammad</creator><creatorcontrib>Mirza, Irfan Ali ; Khan, Farooq Ahmad ; Khan, Khursheed Ali ; Satti, Luqman ; Ghafoor, Tahir ; Fayyaz, Muhammad</creatorcontrib><description>To find out the frequency of Extensively Drug Resistant (XDR) and pre-XDR tuberculosis in clinical isolates of Multi-Drug Resistant (MDR) Tuberculosis (TB) by determining the susceptibilities against Levofloxacin and Amikacin (classical second line antituberculosis drugs).
Adescriptive cross-sectional study.
Microbiology Department, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from September 2011 to August 2013.
Amikacin (AK) and Levofloxacin (LEVO) were obtained in chemically pure form from Sigma (Taufkirchen, Germany). The breakpoint concentration used for AK was 1.0 µg/ml and for LEVO 2.0 µg/ml. Mycobacterial Growth Indicator Tube (MGIT) 960 system was used to carry out drug susceptibility testing as per recommended protocol.
A total of 3 MDR-TB isolates (3%) turned out to be XDR-TB based upon simultaneous resistance to injectable second line antituberculosis drug AK and one of the fluoro-quinolones (LEVO). A total of 24 MDR-TB isolates (24%) were found to be pre-XDR based upon resistance to LEVO alone. Treatment status record of patients with XDR and pre-XDRTB isolates revealed that majority of patients had received fluoroquinolones (FQs) during the course of treatment.
XDR-TB has started to emerge in MDR-TB isolates in our set up. The worrying sign is the high frequency of pre-XDR tuberculosis. Urgent steps need to be taken to stem the tide of pre-XDR-TB in our population. It is thus recommended to develop facilities to carry out drug susceptibility testing to monitor the status of pre-XDR and XDR-TB in our population.</description><identifier>ISSN: 1022-386X</identifier><identifier>EISSN: 1681-7168</identifier><identifier>PMID: 26008658</identifier><language>eng</language><publisher>Pakistan: College of Physicians and Surgeons Pakistan</publisher><subject>Amikacin ; Amikacin - therapeutic use ; Antitubercular Agents - therapeutic use ; Cross-Sectional Studies ; Distribution ; Dosage and administration ; Drug therapy ; Extensively Drug-Resistant Tuberculosis - diagnosis ; Extensively Drug-Resistant Tuberculosis - drug therapy ; Female ; Humans ; Levofloxacin ; Levofloxacin - therapeutic use ; Microbial Sensitivity Tests ; Middle Aged ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Tuberculosis ; Young Adult</subject><ispartof>Journal of the College of Physicians and Surgeons--Pakistan, 2015-05, Vol.25 (5), p.337-341</ispartof><rights>COPYRIGHT 2015 College of Physicians and Surgeons Pakistan</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26008658$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mirza, Irfan Ali</creatorcontrib><creatorcontrib>Khan, Farooq Ahmad</creatorcontrib><creatorcontrib>Khan, Khursheed Ali</creatorcontrib><creatorcontrib>Satti, Luqman</creatorcontrib><creatorcontrib>Ghafoor, Tahir</creatorcontrib><creatorcontrib>Fayyaz, Muhammad</creatorcontrib><title>Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin)</title><title>Journal of the College of Physicians and Surgeons--Pakistan</title><addtitle>J Coll Physicians Surg Pak</addtitle><description>To find out the frequency of Extensively Drug Resistant (XDR) and pre-XDR tuberculosis in clinical isolates of Multi-Drug Resistant (MDR) Tuberculosis (TB) by determining the susceptibilities against Levofloxacin and Amikacin (classical second line antituberculosis drugs).
Adescriptive cross-sectional study.
Microbiology Department, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from September 2011 to August 2013.
Amikacin (AK) and Levofloxacin (LEVO) were obtained in chemically pure form from Sigma (Taufkirchen, Germany). The breakpoint concentration used for AK was 1.0 µg/ml and for LEVO 2.0 µg/ml. Mycobacterial Growth Indicator Tube (MGIT) 960 system was used to carry out drug susceptibility testing as per recommended protocol.
A total of 3 MDR-TB isolates (3%) turned out to be XDR-TB based upon simultaneous resistance to injectable second line antituberculosis drug AK and one of the fluoro-quinolones (LEVO). A total of 24 MDR-TB isolates (24%) were found to be pre-XDR based upon resistance to LEVO alone. Treatment status record of patients with XDR and pre-XDRTB isolates revealed that majority of patients had received fluoroquinolones (FQs) during the course of treatment.
XDR-TB has started to emerge in MDR-TB isolates in our set up. The worrying sign is the high frequency of pre-XDR tuberculosis. Urgent steps need to be taken to stem the tide of pre-XDR-TB in our population. It is thus recommended to develop facilities to carry out drug susceptibility testing to monitor the status of pre-XDR and XDR-TB in our population.</description><subject>Amikacin</subject><subject>Amikacin - therapeutic use</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Cross-Sectional Studies</subject><subject>Distribution</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Extensively Drug-Resistant Tuberculosis - diagnosis</subject><subject>Extensively Drug-Resistant Tuberculosis - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Levofloxacin - therapeutic use</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Tuberculosis</subject><subject>Young Adult</subject><issn>1022-386X</issn><issn>1681-7168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UdtKxDAQLaK46-ovSMCX9aHSJr2kj8uyXmDBFwXfSppMSjRt1iSV3e_yB81eBAWRwCQ5OWfOzOQoGqcFTeMyxONwTjCOCS1eRtGZc69JQvKU0tNohIskoUVOx9HnYu2hd-oD9AaxXqCVhRh-YMIOLbLglPOs98gPDVg-aBMApHrEteoVZxopZzTz4JCRqBu0V_F_ysGpvg1i5txO7YCbYB6Swc7RoamGDyO1WTMebLaVsU69bS_X59GJZNrBxWGfRM-3i6f5fbx8vHuYz5Zxi0vqY1kQigVnJfA8FZRmBGeZoITwNPTPWcXLRDRFzhJSyZSmAgtchWfW8ApXUpJJNN3nXVnzPoDzdaccB61ZD2ZwdRgyyUuCyypQr_bUlmmoVS-Nt4xv6fUsSzOKswKXgXXzByssAZ0KAwCpAv5LcHmoYGg6EPXKqo7ZTf39f-QL7Mmb6g</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Mirza, Irfan Ali</creator><creator>Khan, Farooq Ahmad</creator><creator>Khan, Khursheed Ali</creator><creator>Satti, Luqman</creator><creator>Ghafoor, Tahir</creator><creator>Fayyaz, Muhammad</creator><general>College of Physicians and Surgeons Pakistan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin)</title><author>Mirza, Irfan Ali ; Khan, Farooq Ahmad ; Khan, Khursheed Ali ; Satti, Luqman ; Ghafoor, Tahir ; Fayyaz, Muhammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g278t-f6382dca7ec51d8843244d833c1260ca9c70db65a039f181d2d29833abc929ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amikacin</topic><topic>Amikacin - therapeutic use</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Cross-Sectional Studies</topic><topic>Distribution</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Extensively Drug-Resistant Tuberculosis - diagnosis</topic><topic>Extensively Drug-Resistant Tuberculosis - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Levofloxacin - therapeutic use</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Tuberculosis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mirza, Irfan Ali</creatorcontrib><creatorcontrib>Khan, Farooq Ahmad</creatorcontrib><creatorcontrib>Khan, Khursheed Ali</creatorcontrib><creatorcontrib>Satti, Luqman</creatorcontrib><creatorcontrib>Ghafoor, Tahir</creatorcontrib><creatorcontrib>Fayyaz, Muhammad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the College of Physicians and Surgeons--Pakistan</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mirza, Irfan Ali</au><au>Khan, Farooq Ahmad</au><au>Khan, Khursheed Ali</au><au>Satti, Luqman</au><au>Ghafoor, Tahir</au><au>Fayyaz, Muhammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin)</atitle><jtitle>Journal of the College of Physicians and Surgeons--Pakistan</jtitle><addtitle>J Coll Physicians Surg Pak</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>25</volume><issue>5</issue><spage>337</spage><epage>341</epage><pages>337-341</pages><issn>1022-386X</issn><eissn>1681-7168</eissn><abstract>To find out the frequency of Extensively Drug Resistant (XDR) and pre-XDR tuberculosis in clinical isolates of Multi-Drug Resistant (MDR) Tuberculosis (TB) by determining the susceptibilities against Levofloxacin and Amikacin (classical second line antituberculosis drugs).
Adescriptive cross-sectional study.
Microbiology Department, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from September 2011 to August 2013.
Amikacin (AK) and Levofloxacin (LEVO) were obtained in chemically pure form from Sigma (Taufkirchen, Germany). The breakpoint concentration used for AK was 1.0 µg/ml and for LEVO 2.0 µg/ml. Mycobacterial Growth Indicator Tube (MGIT) 960 system was used to carry out drug susceptibility testing as per recommended protocol.
A total of 3 MDR-TB isolates (3%) turned out to be XDR-TB based upon simultaneous resistance to injectable second line antituberculosis drug AK and one of the fluoro-quinolones (LEVO). A total of 24 MDR-TB isolates (24%) were found to be pre-XDR based upon resistance to LEVO alone. Treatment status record of patients with XDR and pre-XDRTB isolates revealed that majority of patients had received fluoroquinolones (FQs) during the course of treatment.
XDR-TB has started to emerge in MDR-TB isolates in our set up. The worrying sign is the high frequency of pre-XDR tuberculosis. Urgent steps need to be taken to stem the tide of pre-XDR-TB in our population. It is thus recommended to develop facilities to carry out drug susceptibility testing to monitor the status of pre-XDR and XDR-TB in our population.</abstract><cop>Pakistan</cop><pub>College of Physicians and Surgeons Pakistan</pub><pmid>26008658</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1022-386X |
| ispartof | Journal of the College of Physicians and Surgeons--Pakistan, 2015-05, Vol.25 (5), p.337-341 |
| issn | 1022-386X 1681-7168 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1683573279 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Amikacin Amikacin - therapeutic use Antitubercular Agents - therapeutic use Cross-Sectional Studies Distribution Dosage and administration Drug therapy Extensively Drug-Resistant Tuberculosis - diagnosis Extensively Drug-Resistant Tuberculosis - drug therapy Female Humans Levofloxacin Levofloxacin - therapeutic use Microbial Sensitivity Tests Middle Aged Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Tuberculosis Young Adult |
| title | Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T10%3A29%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extensively%20and%20pre-extensively%20drug%20resistant%20tuberculosis%20in%20clinical%20isolates%20of%20multi-drug%20resistant%20tuberculosis%20using%20classical%20second%20line%20drugs%20(levofloxacin%20and%20amikacin)&rft.jtitle=Journal%20of%20the%20College%20of%20Physicians%20and%20Surgeons--Pakistan&rft.au=Mirza,%20Irfan%20Ali&rft.date=2015-05-01&rft.volume=25&rft.issue=5&rft.spage=337&rft.epage=341&rft.pages=337-341&rft.issn=1022-386X&rft.eissn=1681-7168&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA414824627%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1683573279&rft_id=info:pmid/26008658&rft_galeid=A414824627&rfr_iscdi=true |